Loading…
Good Girl LLC dba GoodGirlRX was cited for misbranding compounded semaglutide and tirzepatide products in violation of the Federal Food, Drug, and Cosmetic Act. The company falsely represented itself as the compounder of these drugs on its website when it was not, and made unsubstantiated claims that the products were "FDA-approved" and "clinically proven," despite compounded drugs not receiving FDA approval. These false or misleading claims regarding drug labeling and advertising resulted in misbranded products being introduced into interstate commerce.